Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

Although imatinib is clearly the treatment of choice for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia (CEL), little is known about optimal dosing, duration of treatment, and the possibility of cure in this disorder. To address these questions, 5 patients with FIP1L1/PDGFRA-positive CEL with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Klion, Amy D., Robyn, Jamie, Maric, Irina, Fu, Weiming, Schmid, Laura, Lemery, Steven, Noel, Pierre, Law, Melissa A., Hartsell, Marilyn, Talar-Williams, Cheryl, Fay, Michael P., Dunbar, Cynthia E., Nutman, Thomas B.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2007
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2077306/
https://ncbi.nlm.nih.gov/pubmed/17709602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-07-100164
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares